|

A Study of Sovilnesib in Subjects With Ovarian Cancer

RECRUITINGPhase 1Sponsored by Volastra Therapeutics, Inc.
Actively Recruiting
PhasePhase 1
SponsorVolastra Therapeutics, Inc.
Started2024-04-04
Est. completion2027-11
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations11 sites

Summary

This is a phase 1b study to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of sovilnesib at different dose levels to establish the optimal dose of sovilnesib in subjects with selected advanced solid tumors.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Key Inclusion Criteria:

* All Parts: Age ≥ 18 years, ECOG Performance Status ≤ 1, at least 1 site of measurable disease evaluable by CT scan or MRI per RECIST 1.1, able to take oral medication without alteration
* Histologically confirmed locally advanced, inoperable, or metastatic tumor.
* High Grade Serous Ovarian Cancer, Fallopian Tube or Primary Peritoneal Cancer - histologically confirmed; locally advanced, inoperable or metastatic; p16 positive (Part 2 only); platinum resistant (defined as radiographic progression/recurrence \<180 days after last dose of ≥ 4 cycles of platinum containing therapy) or refractory; prior bevacizumab treatment, unless ineligible or intolerant; if germline and/or somatic BRCA1/2 mutation, previously treated with PARP-inhibitor (unless ineligible or intolerant).

Key Exclusion Criteria:

* Part 1 only: MSI-H, dMMR, POLE gene hotspot mutated, or known hypermutator phenotype
* Endometrioid, clear cell, mucinous, sarcomatoid, low-grade/borderline ovarian tumor or mixed tumors containing any of the above histologies
* Previously received KIF18A inhibitor
* Leptomeningeal disease, or new or progressive CNS metastases or spinal cord compression
* Cardiac parameters: MI, PE, CABG, severe/unstable angina or stroke ≤ 6 months, NYHA Class ≥ II, LVEF \< 50%
* Any gastrointestinal condition (e.g. malabsorption syndrome, surgical anastomosis, short bowel syndrome) that might affect the absorption of oral medications including the study drug

Conditions5

CancerChromosomal InstabilityFallopian Tube CancerHigh Grade Serous Adenocarcinoma of OvaryPrimary Peritoneal Carcinoma

Interventions1

Locations11 sites

The University of Alabama at Birmingham
Birmingham, Alabama, 35294
Charles A. Leath, III, MD205-934-4986
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Hoag Memorial Hospital
Newport Beach, California, 92663
Georgia Cancer Center Augusta University
Gwendolyn Stanley, RN706-721-3473gstanley@augusta.edu
Johns Hopkins Hospital

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.